Cholesterol LDL and

Levels of total cholesterol, LDL and FfDL significantly reduced Levels of LDL significantly reduced... 

Lipids - Rosiglitazone as monotherapy was associated with increases in total cholesterol, LDL, and HDL and decreases in free fatty acids. Patients treated with pioglitazone had mean decreases in triglycerides, mean increases in HDL cholesterol. 

The statins are considered as a major breakthrough in the development of hypolipaemic drugs. These agents inhibit the biosynthesis of cholesterol (Fig. 8) and also increase the density of LDL-receptors. They induce a potent lowering of total cholesterol, LDL, and a weak lowering effect on the triglycerides. The plasma HDL-cholesterol level is moderately enhanced. 

The VLDL cholesterol is calculated as the difference from total cholesterol minus the bottom-layer cholesterol (LDL and HDL) and directly from the top-layer cholesterol (VLDL). 

In the 80-mg simvastatin dose group in the Ato Z trial, CRP levels fell from 20,1 to 1,7 at four months and 1,5 at eight months (P < 0.001) (36). Higher-dose simvastatin resulted in lower CRP levels. In PROVE-IT (35), Ato Z (36), and MIRACL trials (37), higher doses of statin medications resulted in lower low-density cholesterol (LDL) and a better outlook. Higher doses of statin also caused greater falls in CRP levels. This suggests a role for inflammation in these ACS patients (37). 

Absorption, digestion, and metabolism studies have been conducted on caprenin (21, 22). Several clinical studies suggested that, despite its lower energy content, caprenin slightly increased lipoprotein levels. In one study, with 30 adult males fed caprenin at 34 g/day for eight weeks, total serum cholesterol, LDL, and HDL were increased by 8%, 20%, and 13%, respectively (23). 

Ezetimibe is an antihyperlipidemic agent that inhibits absorption of cholesterol by the small intestine. It is indicated to be administered alone or with HMG-CoA reductase inhibitors as adjnnctive therapy to diet for reduction of elevated total cholesterol, LDL, and apolipoprotein (Apo) in patients with primary hypercholesterolemia with atorv-astatin or simvastatin for the reduction of elevated total cholesterol and LDL levels in patients with homozygous familial hypercholesterolemia as an adjunct to other lipidlowering treatments or if such treatments are unavailable and as adjnnctive therapy to diet for the reduction of elevated sitosterol and campesterol levels in patients with homozygons familial sitosterolemia. 

The randomised, double blind, placebo-controlled SENSE trial of 157 treatment naive subjects comparing two nucleoside analogues plus either 400 mg etravirine once daily or 600 mg EFV once daily found fewer grade 3 and 4 lipid elevations in total cholesterol, LDL and triglycerides in the EFV group [234 ]. 

Blood lipid profiles were measured during the studies and consisted of total cholesterol, high-density lipoprotein cholesterol (HDL), very low-density lipoprotein cholesterol (VLDL), low-density lipoprotein cholesterol (LDL), and triglycerides. In HMB-supplemented snbjects, HDL cholesterol showed no change, while in the placebo-supplemented subjects, a 4% increase in HDL cholesterol was seen (p < 0.04). Of particnlar interest is that supplemental HMB significantly (p < 0.03) lowered total cholesterol by 3.7% in all snbjects and by 5.8% in subjects with cholesterol levels over 200 mg/dl. The decrease in total cholesterol with HMB supplementation was mainly the result of a significant decrease in LDL cholesterol... 

An analysis has been reported of relationship of lipids and lipoproteins to development of coronary heart disease (CHD) over 14 years in 5127 men and women in the Framingham Study. Serum cholesterol, LDL and VLDL showed strong statistical discriminatory power for development of CHD, VLDL somewhat less than the other two. In men of all ages and in young women VLDL did not predict CHD when its cholesterol risk factor was statistically removed. In women of 54-69 years, however, VLDL appeared to be the important risk factor, rather than cholesterol. With the exception of these older women, the data seem to indicate that cholesterol, presented to the artery either as LDL or VLDL, is the pathogenic agent. 

Cholesterol is biosynthesized in the liver trans ported throughout the body to be used in a va riety of ways and returned to the liver where it serves as the biosynthetic precursor to other steroids But cholesterol is a lipid and isn t soluble in water How can it move through the blood if it doesn t dis solve in if The answer is that it doesn t dissolve but IS instead carried through the blood and tissues as part of a lipoprotein (lipid + protein = lipoprotein) The proteins that carry cholesterol from the liver are called low density lipoproteins or LDLs those that return it to the liver are the high-density lipoproteins or HDLs If too much cholesterol is being transported by LDL or too little by HDL the extra cholesterol builds up on the walls of the arteries caus mg atherosclerosis A thorough physical examination nowadays measures not only total cholesterol con centration but also the distribution between LDL and HDL cholesterol An elevated level of LDL cholesterol IS a risk factor for heart disease LDL cholesterol is bad cholesterol HDLs on the other hand remove excess cholesterol and are protective HDL cholesterol IS good cholesterol... 

Defects in the LDL receptor have been particularly well explored as a basis of the disease familial hypercholesterolemia (93,111). A number of defects that collectively impair LDL receptor trafficking, binding, or deUvery underHe this disease where LDL and semm cholesterol rise to levels that mediate early cardiovascular mortaUty. Studies of the population distribution of this defect can determine the source of the original mutation. Thus, in Quebec, about 60% of the individuals suffering from familial hypercholesterolemia have a particular 10-kdobase deletion mutation in the LDL gene (112). This may have arisen from an original founder of the French Canadian settiement in the seventeenth century. 

The distribution between LDL and HDL cholesterol depends mainly on genetic factors, but can be... 

The relative amounts of LDL and HDL cholesterol in your bloodstream depend, at least in part, on your diet In particular, they depend on the total amount and the type of fat that you eat. Fats (triglycerides) are esters of glycerol with long-chain carboxylic acids. The general structure of a fat can be represented as... 

For ISIS 301012, a second-generation antisense inhibitor of apoB-100 in November 2006. Isis announced results from two Phase 2 clinical trials of ISIS 301012. In the first study repotted, patients with high cholesterol on stable doses of statins were treated with ISIS 301012 for 5 weeks. Patients who received 300 mg/week of ISIS 301012 in this study achieved a 51% reduction in LDL-cholesterol (LDL), a 42% reduction in total cholesterol (TC), and a 4l% reduction in triglycerides (TG) beyond the levels achieved with statins alone. 

LDL is the major carrier of cholesterol to the periphery and supplies the cholesterol essential for the integrity of nerve tissue, steroid hormone synthesis, and cell membranes. The association between elevated plasma cholesterol carried in LDL and the risk of coronary heart disease has been well established. LDL is also sometimes called the bad cholesterol. 

Discuss cholesterol, HDL, LDL, and triglyceride levels and how they contribute to the development of heart disease. 

A daily intake of 25 and 30 g of GA for 21 to 30 days reduced total cholesterol by 6 and 10.4%, respectively (Ross et al., 1983, Sharma 1985). The decrease was limited only to LDL and VLDL, with no effect on HDL and triglycerides. However, Topping et al. (1985) reported that plasma cholesterol concentrations were not affected by the supply of GA, but triglyceride concentration in plasma was significantly lower than in controls. 

Figure 26-5. Factors affecting cholesterol balance at the cellular level. Reverse cholesterol transport may be initiated by pre 3 HDL binding to the ABC-1 transporter protein via apo A-l. Cholesterol is then moved out of the cell via the transporter, lipidating the HDL, and the larger particles then dissociate from the ABC-1 molecule. (C, cholesterol CE, cholesteryl ester PL, phospholipid ACAT, acyl-CoA cholesterol acyltransferase LCAT, lecithinicholesterol acyltransferase A-l, apolipoprotein A-l LDL, low-density lipoprotein VLDL, very low density lipoprotein.) LDL and HDL are not shown to scale.

---